A phase I study of GKT-771
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs GKT 771 (Primary)
- Indications Cancer; Inflammation; Pain
- Focus Adverse reactions
- 26 Oct 2017 According to a GenKyoTex media release, the company intends to submit a clinical trial application (CTA) by the 2 end of 2017 and if approved the study is anticipated to start at the beginning of 2018 and first results could be available in the first half of 2018.
- 27 Jul 2017 According to a GenKyoTex media release, this study is anticipated to start at the end of 2017.
- 02 Jan 2017 New trial record